SENTINEL LYMPH NODE SCINTIGRAPHY IN BREAST CARCINOMA- COMPARISON OF TWO VERSUS FOUR INJECTION SITE TECHNIQUE
Abstract
Purpose: Sentinel lymph node (SLN) is the first regional node that drains lymph from the primary tumour and receives seeding of metastatic cells. Axillary node dissection remains the most reliable predictor of disease outcome. Controversies still exist about several aspects of lymphatic mapping and SLN biopsy for breast cancer, including number of radioisotope injection. The purpose of this study is to evaluate the success rate of different number of injection sites in the detection of SLN in breast cancer.
Materials and Methods: A total of 120 consecutive breast cancer patients were divided into two groups. Group A (60 patients) received four intradermal periareolar (ID-PA) injections. Group B (60 patients) received two ID-PA injections.Imaging was carried out at 45 min post-injection. A gamma probe was used to explore the SLNs during surgery.
Results: In Group A, 60 females with the mean age of 50.77 years were included in the study. 34 (56%) patients had single SLN. 25 (41.7%) had SLN with the second tier. 1 (1.7%) was negative. Group B included 60 patients (59 females and 1 male) with the mean age of 51.9 years. In 30 (50%) patients, single SLN was detected. 29 (48.3%) had SLN with the second tier. 1 (1.7%) was negative.
Conclusion: SLN mapping with two periareolar ID injections carries less radiation dose and less pain as compared to the four injections with equal sensitivity for the visualization of SLNs.
Key words: Breast cancer, intradermal injection, sentinel lymph node, Tc99 human serum albumin
References
Sohail S, Alam SN. Breast cancer in Pakistan-awareness and early detection. J Coll Physicians Surg Pak 2007;17:711-2.
Bennett JJ. Sentinel lymph node biopsy for breast cancer
and melanoma. Oncology 2006;1:22.
Paulo RM, Nilton LX, Spiro BL, et al. Scintigraphic sentinel node detection in breast cancer patients: Paired and blinded comparison of Dextran500-99mTc and Phytate-99mTc.Alasbimn J 2006;8:1087-91.
Kaplan RJ, Meier RH 3rd. Breast Cancer and Rehabilitation. Available from: http://www.emedicine.medscape.com/ article/320261 overview#aw2aab6b3. [Last accessed on 2011 May 26].
Scoggins CR, Chagpar AB, Martin RC, et al. Sentinel lymph-node biopsy be used routinely for staging melanoma and breast cancers? Nat Pract Oncol 2005;2:448-55.
Mudun A, Sanli Y, Ozmen V, et al. Comparison of different injection sites of radionuclide for sentinel lymph node detection in breast cancer: Single institution experience. Clin Nucl Med 2008;33:262-7.
Kumar R, Dhurairaj T, Jana S, et al. Overview of sentinel
lymph node mapping in breast cancer. Ind J Nucl Med 2003;18:46-51.
Cody HS 3rd. Clinical aspects of sentinel node biopsy. Breast Cancer Res 2001;3:104-8.
Uren RF, Howman-Giles RB, Thompson JF, et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med 1995;36:1775-80.
Uren RF, Thompson JF, Howman-Giles R. Sentinel-lymph
node biopsy in breast cancer. Lancet 1998;352:1472-3.
McMasters KM, Wong SL, Martin RC 2nd, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: Results of a multiinstitutional study. Ann Surg 2001;233:676-87.
Pelosi E, Baiocco C, Ala A, et al. Lymphatic mapping in early stage breast cancer: Comparison between periareolar and subdermal injection. Nucl Med Commun 2003;24:519-23.
Celliers L, Mann GB. Alternative sites of injection for sentinel lymph node biopsy in breast cancer. ANZ J Surg 2003;73:600-4.
Kern KA, Rosenberg RJ. Preoperative lymphoscintigraphy during lymphatic mapping for breast cancer: Improved sentinel node imaging using subareolar injection of technetium 99m sulfur colloid. J Am Coll Surg 2000;191:479-89.
Linehan DC, Hill AD, Tran KN, et al. Sentinel lymph node biopsy in breast cancer: Unfiltered radioisotope is superior to filtered. J Am Coll Surg 1999;188:377-81.
De Cicco C, Cremonesi M, Luini A, et al. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med 1998;39:2080-4.
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-53.
McMasters KM, Wong SL, Tuttle TM, et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg 2000;231:724-31.
Shivers S, Cox C, Leight G, et al. Final results of the department of defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 2002;9:248-55.
Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001;233:51-9.
Schrenk P, Rehberger W, Shamiyeh A, et al. Sentinel node biopsy for breast cancer: Does the number of sentinel nodes removed have an impact on the accuracy of finding a positive node? J Surg Oncol 2002;80:130-6.
Heuser T, Rink T, Weller E, et al. Impact of the axillary nodal status on sentinel node mapping in breast cancer and its relevance for technical proceeding. Breast Cancer Res Treat 2001;67:125-32.
Lo YF, Hsueh S, Ma SY, et al. Clinical relevance of nonvisualized sentinel lymph nodes in unselected breast cancer patients during lymphoscintigraphy. Chang Gung Med J 2005;28:378-86.
Kroon BK, Valdés Olmos R, Nieweg OE, et al. Nonvisualization of sentinel lymph nodes in penile carcinoma. Eur J Nucl Med Mol Imaging 2005;32:1096-9.
Bajén MT, Benítez A, Mora J, et al. Subdermal re-injection: A method to increase surgical detection of the sentinel node in breast cancer without increasing the false-negative rate. Eur J Nucl Med Mol Imaging 2006;33:338-43.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.
